Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 9/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 7/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 6/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 4/20 | 1.00 |
| ▸ | CARM1 | Q86X55 | 2/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 2/20 | 1.00 |
| ▸ | NNMT | P40261 | 2/20 | 1.00 |
| ▸ | TRDMT1 | O14717 | 1/20 | 1.00 |
| ▸ | PRMT5 | O14744 | 1/20 | 1.00 |
| ▸ | SUV39H1 | O43463 | 1/20 | 1.00 |
| ▸ | PRMT3 | O60678 | 1/20 | 1.00 |
| ▸ | INMT | O95050 | 1/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | PNMT | P11086 | 1/20 | 1.00 |
| ▸ | HNMT | P50135 | 1/20 | 1.00 |
| ▸ | WDR5 | P61964 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SETDB1 | Q15047 | 1/20 | 1.00 |
| ▸ | RBBP5 | Q15291 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Adenosylhomocysteine SCHEMBL804238 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL13033864 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL10871157 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL17087726 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL14434697 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL18826562 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL17316165 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL13073142 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL21160481 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL14411397 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613552-B2 | Pharmaceutical agents, compositions, and methods relating thereto | ALLTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2021-08-05 | — | — | US | disclosed |
| US-11014954-B2 | Pharmaceutical agents, compositions, and methods relating thereto | ALLTECH, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200123191-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | ALLTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| US-10337049-B2 | Universal methylation profiling methods | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-07-02 | — | — | US | disclosed |
| US-20160355542-A1 | UNIVERSAL METHYLATION PROFILING METHODS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | BAYLOR COLLEGE OF MEDICINE (US) | 2016-06-16 | — | — | US | disclosed |
| US-20130004947-A1 | LUCIFERASE-LINKED ANALYSIS OF DNA-METHYLTRANSFERASE, PROTEIN METHYLTRANSFERASE AND S-ADENOSYLHOMOCYSTEINE AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2013-01-03 | — | — | US | disclosed |
| US-8008007-B2 | S-adenosyl-L-methionine analogs with extended activated groups for transfer by methyltransferases | RWTH AACHEN (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | RWTH AACHEN (DE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238216-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | PCSK9, PCSK7, PDE3A | DOT1L 4783/4885DNMT1 4842/4885DNMT3B 4801/4885 |
| US-20160355542-A1 | UNIVERSAL METHYLATION PROFILING METHODS | DNMT1, DNMT3A, DNMT3B | DOT1L 64/4885DNMT1 1/4885DNMT3B 3/4885 |
| US-11014954-B2 | Pharmaceutical agents, compositions, and methods relating thereto | PCSK9, PCSK7, PDE3A | DOT1L 4783/4885DNMT1 4842/4885DNMT3B 4801/4885 |
| US-10337049-B2 | Universal methylation profiling methods | DNMT1, DNMT3A, DNMT3B | DOT1L 64/4885DNMT1 1/4885DNMT3B 3/4885 |
| US-11613552-B2 | Pharmaceutical agents, compositions, and methods relating thereto | PCSK9, PCSK7, PDE3A | DOT1L 4783/4885DNMT1 4842/4885DNMT3B 4801/4885 |
| US-20200123191-A1 | PHARMACEUTICAL AGENTS, COMPOSITIONS, AND METHODS RELATING THERETO | PCSK9, PCSK7, PDE3A | DOT1L 4783/4885DNMT1 4842/4885DNMT3B 4801/4885 |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | BHMT2, MSRB3, PRMT3 | DOT1L 96/4885DNMT1 7/4885DNMT3B 17/4885 |
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | DOT1L, CARM1, NSD1 | DOT1L 1/4885DNMT1 40/4885DNMT3B 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.